{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:59:25Z","timestamp":1793401165814,"version":"4.5.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To report a case of intraocular inflammation (IOI) after intravitreal injection of aflibercept 8\u00a0mg for treatment-refractory neovascular age-related macular degeneration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>An 80-year-old man with diabetes mellitus had neovascular age-related macular degeneration refractory to treatment with aflibercept 2\u00a0mg. Despite ten injections of faricimab, the exudation remained, and we switched to brolucizumab, which resulted in a mild IOI. The IOI improved with only topical steroids, and we switched back to aflibercept 2\u00a0mg for the exudation. However, the exudation remained, and we decided to switch to aflibercept 8\u00a0mg after careful discussion with the patient. Two weeks later, he experienced minor ocular pain and photophobia. One month later, although a dry macula was achieved, severe visual impairment occurred due to anterior chamber inflammation, retinal vasculitis, and retinal vascular occlusion. We diagnosed the severe IOI following aflibercept 8\u00a0mg and immediately started steroid eye drops and a sub-Tenon injection of triamcinolone acetonide. Although the inflammation resolved, his visual acuity did not improve.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case demonstrated a potential dose-dependent inflammatory response following aflibercept 8\u00a0mg, which did not occur with aflibercept 2\u00a0mg in patients with a history of intraocular inflammation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-024-03827-6","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T09:55:47Z","timestamp":1737626147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Intraocular inflammation after intravitreal injection of aflibercept 8\u00a0mg for treatment-refractory neovascular age-related macular degeneration: a case report"],"prefix":"10.1186","volume":"25","author":[{"given":"Nozomu","family":"Hashiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Maruko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Miyaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruka","family":"Maruko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"3827_CR1","doi-asserted-by":"crossref","unstructured":"Baumal CR, Spaide RF, Vajzovic L, Freund KB, Walter SD, John V, Rich R, Chaudhry N, Lakhanpal RR, Oellers PR et al. Retinal vasculitis and intraocular inflammation after Intravitreal Injection of Brolucizumab. Ophthalmology 2020, 127(10).","DOI":"10.1016\/j.ophtha.2020.04.017"},{"key":"3827_CR2","doi-asserted-by":"crossref","unstructured":"Maruko I, Okada AA, Iida T, Hasegawa T, Izumi T, Kawai M, Maruko R, Nakayama M, Yamamoto A, Koizumi H et al. Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter study. Graefe\u2019s archive for clinical and experimental ophthalmology\u2009=\u2009Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2021.","DOI":"10.1007\/s00417-021-05136-w"},{"key":"3827_CR3","doi-asserted-by":"publisher","first-page":"101289","DOI":"10.1016\/j.ajoc.2022.101289","volume":"25","author":"SK Kurup","year":"2022","unstructured":"Kurup SK, Tabbaa T, Echegaray JJ, Oliver AL. Intraocular inflammation secondary to intravitreal brolucizumab treated successfully with Sub-tenon triamcinolone: a case report. Am J Ophthalmol Case Rep. 2022;25:101289.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"4","key":"3827_CR4","first-page":"714","volume":"44","author":"S Inoda","year":"2024","unstructured":"Inoda S, Takahashi H, Maruyama-Inoue M, Ikeda S, Sekiryu T, Itagaki K, Matsumoto H, Mukai R, Nagai Y, Ohnaka M, et al. INCIDENCE AND RISK FACTORS OF INTRAOCULAR INFLAMMATION AFTER BROLUCIZUMAB TREATMENT IN JAPAN: a Multicenter Age-Related Macular Degeneration Study. Retina. 2024;44(4):714\u201322.","journal-title":"Retina"},{"issue":"4","key":"3827_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1001\/jamaophthalmol.2024.0530","volume":"142","author":"L Thangamathesvaran","year":"2024","unstructured":"Thangamathesvaran L, Kong J, Bressler SB, Singh M, Wenick AS, Scott AW, Ar\u00e9valo JF, Bressler NM. Severe intraocular inflammation following Intravitreal Faricimab. JAMA Ophthalmol. 2024;142(4):365\u201370.","journal-title":"JAMA Ophthalmol"},{"issue":"10432","key":"3827_CR6","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, Eichenbaum D, Iida T, Xiaodong S, Berliner AJ, et al. Intravitreal aflibercept 8\u00a0mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403(10432):1141\u201352.","journal-title":"Lancet"},{"issue":"9","key":"3827_CR7","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","volume":"141","author":"CC Wykoff","year":"2023","unstructured":"Wykoff CC, Brown DM, Reed K, Berliner AJ, Gerstenblith AT, Breazna A, Abraham P, Fein JG, Chu KW, Clark WL, et al. Effect of high-dose Intravitreal Aflibercept, 8\u00a0mg, in patients with Neovascular Age-Related Macular Degeneration: the phase 2 CANDELA Randomized Clinical Trial. JAMA Ophthalmol. 2023;141(9):834\u201342.","journal-title":"JAMA Ophthalmol"},{"key":"3827_CR8","doi-asserted-by":"crossref","unstructured":"Veritti D, Sarao V, Gorni G, Lanzetta P. Anti-VEGF drugs Dynamics: relevance for clinical practice. Pharmaceutics 2022, 14(2).","DOI":"10.3390\/pharmaceutics14020265"},{"key":"3827_CR9","doi-asserted-by":"crossref","unstructured":"Veritti D, Sarao V, Di Bin F, Lanzetta P. Pharmacokinetic and pharmacodynamic rationale for extending VEGF inhibition increasing Intravitreal Aflibercept Dose. Pharmaceutics 2023, 15(5).","DOI":"10.3390\/pharmaceutics15051416"},{"issue":"9","key":"3827_CR10","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1097\/IAE.0000000000003556","volume":"42","author":"FG Holz","year":"2022","unstructured":"Holz FG, Iida T, Maruko I, Sadda SR, A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Patient selection, evaluation, and treatment. Retina. 2022;42(9):1629\u201337.","journal-title":"Retina"},{"key":"3827_CR11","doi-asserted-by":"crossref","unstructured":"Matsumoto H, Hoshino J, Numaga S, Mimura K, Asatori Y, Akiyama H. Retinal vasculitis after intravitreal aflibercept 8\u00a0mg for neovascular age-related macular degeneration. Jpn J Ophthalmol 2024.","DOI":"10.1007\/s10384-024-01107-w"},{"issue":"16","key":"3827_CR12","doi-asserted-by":"publisher","first-page":"13004","DOI":"10.3390\/ijms241613004","volume":"24","author":"BH Moon","year":"2023","unstructured":"Moon BH, Kim Y, Kim SY. Twenty years of anti-vascular endothelial growth factor therapeutics in Neovascular Age-Related Macular Degeneration Treatment. Int J Mol Sci. 2023;24(16):13004.","journal-title":"Int J Mol Sci"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-024-03827-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-024-03827-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-024-03827-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T20:49:36Z","timestamp":1737665376000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-024-03827-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3827"],"URL":"https:\/\/doi.org\/10.1186\/s12886-024-03827-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5355651\/v1","asserted-by":"object"}]},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was conducted in accordance with the tenets of the Declaration of Helsinki. The institutional review board at Tokyo Women\u2019s Medical University School of Medicine approved the study, which included OCT observation of eyes with macular and retinal disorders, observational study of age-related macular degeneration, and similar disorders.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patients have consented to the submission of this case report to the journal for publication. Written informed consent was obtained for all presented case details and accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Dr. Hashiya receives lecturing and travel fees from Senju Pharmaceutical, Chugai Pharmaceutical, Kowa, Novartis Pharma, and AMO.Dr. Maruko receives lecturing and travel fees from Bayer Pharmaceuticals, Novartis Pharma, Japan Alcon, Santen, Senju Pharmaceutical, Topcon, Chugai Pharmaceutical, Canon, Nidek, and Nikon. He holds a patent.Dr. Miyaguchi has nothing to disclose.Dr. Ruka Maruko receives lecturing and travel fees from Chugai Pharmaceutical and Kyowa Kirin.Dr. Hasegawa receives lecturing and travel fees from Novartis Pharma, Alcon Pharma, Santen, Kowa, Senju Pharmaceutical, R.E. Medical, Nikon Health Care Japan, JFC Sales Plan, Otsuka Pharmaceutical, and Japan Beringer Ingelheim.Dr. Iida receives grants from Nidek, Topcon, Santen, Novartis Pharma, Senju Pharmaceutical, Japan Alcon, HOYA, and AMO, consultant fees from Bayer Pharmaceuticals, Novartis Pharma, Chugai Pharmaceutical, Japan Beringer Ingelheim, and Janssen Pharma, and received lecturing and travel fees from Bayer Pharmaceuticals, Novartis Pharma, Japan Alcon, Santen, Senju Pharmaceutical, Topcon, Chugai Pharmaceutical, Canon, Nidek, Otsuka Pharmaceutical, Nikon, and Kyowa Kirin. He holds a patent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"The author(s) have made the following disclosure(s): funding statement"}}],"article-number":"42"}}